Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 5/20 | 0.42 |
| ▸ | AR | P10275 | 4/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5199219 | 0.81 | NR3C1 (0.33) | NR3C1NFKB1NFKB2RELAKCNH2 | |
| SCHEMBL4978346 | 0.79 | NR3C1 (0.61) | NR3C1ARPGRNR3C2CYP19A1 | |
| SCHEMBL4978357 | 0.79 | NR3C1 (0.61) | NR3C1ARPGRNR3C2CYP19A1 | |
| SCHEMBL4823153 | 0.77 | NR3C1 (0.42) | NR3C1ARPGRNR3C2CYP19A1 | |
| SCHEMBL7113336 | 0.77 | NR3C1 (0.42) | NR3C1ARPGRNR3C2CYP19A1 | |
| SCHEMBL6755263 | 0.77 | NR3C1 (0.42) | NR3C1ARPGRNR3C2CYP19A1 | |
| SCHEMBL7189243 | 0.73 | NR3C1 (0.47) | NR3C1ARPGRNR3C2NFKB1 | |
| SCHEMBL6705112 | 0.70 | NR3C1 (0.47) | NR3C1ARPGRNR3C2CYP19A1 | |
| SCHEMBL6839221 | 0.69 | PGR (0.51) | NR3C1ARPGRNR3C2CYP19A1 | |
| SCHEMBL28472478 | 0.69 | NR3C1 (0.42) | NR3C1ARPGRNR3C2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414127-B2 | used to prepare eplerenone; intermediates | PFIZER INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20070100140-A1 | used to prepare eplerenone; intermediates | PHARMACIA & UPJOHN COMPANY | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100140-A1 | used to prepare eplerenone; intermediates | CYP11B2, CYP11B1, HSD17B7 | NR3C1 74/4885AR 47/4885PGR 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.